On April 24, 2024 Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, reported its upcoming presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2024 Annual Meeting taking place from May 31- June 4, 2024, in Chicago, IL (Press release, Carisma Therapeutics, APR 24, 2024, View Source [SID1234642308]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the poster presentation at ASCO (Free ASCO Whitepaper) 2024 are below:

Poster Title: A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors
Session Title: Developmental Therapeutics—Immunotherapy
Abstract Number: TPS2682
Session Date & Time: Saturday, June 1, 2024, 9:00 AM-12:00 PM CDT

The poster presented at ASCO (Free ASCO Whitepaper) 2024 will be available online in the "Publications" section of Carisma’s website at View Source following the start of the poster session.

On April 24, 2024 Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, reported that results from four clinical studies of the company’s three key drug candidates have been selected for presentations, including an Oral Report, at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Ascentage Pharma, APR 24, 2024, View Source;ascentage-pharma-to-present-four-studies-including-an-oral-report-featuring-the-latest-data-of-olverembatinib-in-sdh-deficient-gist-302126836.html [SID1234642307]). The three drugs are olverembatinib (HQP1351), the first and only China-approved third-generation BCR-ABL inhibitor; lisaftoclax (APG-2575), a Bcl-2-selective inhibitor; and APG-2449, a FAK/ALK/ROS1 inhibitor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ASCO (Free ASCO Whitepaper) Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the clinical oncology community. This year’s ASCO (Free ASCO Whitepaper) Annual Meeting will take place both online and in-person at the McCormick Place, Chicago, IL, the United States, on May 31–June 4, 2024 (local time).

"Entering the seventh consecutive year for our studies to be selected for presentations at the ASCO (Free ASCO Whitepaper) Annual Meeting, we are honored to have the opportunity to once again showcase our capabilities in global innovation and clinical development at this top international scientific meeting," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "Our presentations this year include an Oral Report featuring updated data of olverembatinib in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST), an indication that currently has no effective treatment. Furthermore, we will release detailed data of lisaftoclax in patients with acute myeloid leukemia (AML) and in patients with Waldenstrom macroglobulinemia (WM), as well as those of APG-2449 in patients with non-small cell lung cancer (NSCLC). We look forward to sharing the detailed results from those studies with our colleagues at the meeting. Moving forward, we will remain dedicated to those global clinical development programs of key candidates to hopefully bring more treatment options to patients in need."

These four clinical studies to be presented at this year’s ASCO (Free ASCO Whitepaper) Annual Meeting are as follows:

Olverembatinib
Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) and paraganglioma
Abstract#: 11502
Format: Oral Report
Session Title: Sarcoma
Date and Time: June 3, 2024, Monday, 3:00 PM – 6:00 PM (Central Time)
First Author: Haibo Qiu, MD, PhD, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

APG-2575 (Lisaftoclax)
Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia
Abstract#: 6541
Format: Poster Presentation
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date and Time: June 3, 2024, Monday, 9:00 AM – 12:00 PM (Central Time)
First Author: Huafeng Wang, MD, PhD, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM)
Abstract#: 7078
Format: Poster Presentation
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Date and Time: June 3, 2024, Monday, 9:00 AM– 12:00 PM (Central Time)
First Author: Masa Lasica, MBBS, FRACP, FRCPA, St Vincent’s Hospital, Melbourne, Victoria, Australia.

APG-2449
Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors.
Abstract#: 3124
Format: Poster Presentation
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date and Time: June 1, 2024, Saturday, 9:00 AM – 12:00 PM (Central Time)
First Author: Yuxiang Ma, MD, PhD, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

On April 24, 2024 Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, reported that about 20 accepted abstracts of clinical data from multiple trials in relation to multiple novel mono-/bi-specific antibodies and antibody-drug-conjugates (ADCs) as well as innovative drugs including TYVYT (sintilimab injection), olverembatinib, taletrectinib (ROS1 TKI) from its oncology pipeline will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2024 from May 31 to June 4, 2024, in Chicago, IL, U.S (Press release, Innovent Biologics, APR 24, 2024, View Source [SID1234642306]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Hui Zhou, Senior Vice President of Innovent, stated: "We are very pleased to present a robust set of clinical data for our next-generation innovative bispecific antibodies and ADC molecules for the first time at the 2024 ASCO (Free ASCO Whitepaper) Annual Meeting. We observed the preliminary efficacy and safety signals for those innovative candidates, underscoring their potential for further development and clinical value. As one of the few biopharmaceutical companies with both the technology platforms and robust pipeline in "IO+ADC" areas, Innovent will continue to make breakthroughs in the field of cancer treatment, and is committed to providing doctors and patients with more innovative, effective and safe treatment options."

Details on the abstracts are listed below:

Abstract Title

Abstract No.

Session Type and Title

Presentation Time (CDT)

Presenter

IBI363 (PD-1/IL-2 bispecific antibody)

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study.

3593

Poster Session

-Gastrointestinal Cancer

-Colorectal and Anal

6/1/2024

1:30 PM

-4:30 PM

Dr. Yiwen Chen

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.

9562

Poster Session

-Melanoma/Skin Cancers

6/1/2024

1:30 PM

-4:30 PM

Dr. Yu Chen

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with other solid tumors: Safety and efficacy results from a phase I study.

e14593

Online publication

5/23/2024

5:00 PM

Dr. Xueli Bai

IBI389 (anti-CLDN18.2/CD3 bispecific antibody)

Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study.

2519

Rapid Oral Abstract

-Developmental Therapeutics

-Immunotherapy

6/2/2024

11:30AM

-1:00 PM

Dr. Li Zheng

Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study.

4011

Clinical Science Symposium（Oral）-Building Novel Antibody-Based Approaches in Gastrointestinal Cancers

6/2/2024

4:30 PM

-6:00 PM

Dr. Jihui Hao

IBI343(anti-CLDN18.2 ADC)

Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study.

3037

Poster Session

-Developmental Therapeutics

-Molecularly Targeted Agents and Tumor Biology

6/1/2024

9:00 AM

-12:00 PM

Dr. Xianjun Yu

IBI310 (anti-CTLA-4 antibody)

Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study.

3505

Oral Abstract Session

-Gastrointestinal Cancer

-Colorectal and Anal

6/2/2024

8:00 AM

-11:00 AM

Dr. Rui-Hua Xu

Taletrectinib (ROS1 TKI)

Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.

8520

Rapid Oral Abstract

-Lung Cancer

-Non-Small Cell Metastatic

6/1/2024

4:30PM

-6:00 PM

Dr. Wei Li

IBI110 (anti-LAG-3 antibody)

Efficacy and safety of IBI110 (anti-LAG-3 antibody) plus sintilimab (anti-PD-1 antibody) in patients with advanced alveolar soft part sarcoma: Results from a phase II study.

11559

Poster Session

-Sarcoma

6/1/2024

1:30 PM

-4:30 PM

Dr. Jiayong Liu

TYVYT(sintilimab)[1]

Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.

5512

Rapid Oral Abstract

-Gynecologic Cancer

6/1/2024

8:00 AM

-9:30 AM

Dr. Jihong Liu

Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: single-arm, phase II trial.

6011

Clinical Science Symposium (Oral) -making the Cut: Decision Support Tools in Surgically Treated HPV+ Oropharyngeal Cancer

6/3/2024

3:00 PM

-4:00 PM

Dr. Ming Song and Dr. Shida Yan

Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and dedifferentiated liposarcoma (DDLPS): A single-arm phase 2 trial.

11505

Oral Abstract Session

-Sarcoma

6/3/2024

3:00 PM

-6:00 PM

Dr. Zhiguo Luo

Updated survival results of BBCAPX-II: sintilimab combined with bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.

3563

Poster Session

-Colorectal and Anal

6/1/2024

1:30 PM

-4:30 PM

Dr. Ying Yuan

Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA).

4037

Poster Session

-Gastrointestinal Cancer

-Gastroesophageal, Pancreatic, and Hepatobiliary

6/1/2024

1:30 PM

-4:30 PM

Dr. Zhichao Jiang

Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: A multi-center, open-label, single-arm, phase II study (SAFH).

4523

Poster Session

-Genitourinary Cancer

-Kidney and Bladder

6/2/2024

9:00 AM

-12:00 AM

Dr. Hao Zeng

Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.

4544

Poster Session

-Genitourinary Cancer

-Kidney and Bladder

6/2/2024

9:00 AM

-12:00 AM

Dr. Pei Dong

Fruquintinib plus sintilimab in treated advanced endometrial cancer (EMC) patients (pts) with PMMR status: Results from a multicenter, single-arm phase 2 study.

5619

Poster Session

-Gynecologic Cancer

6/3/2024

9:00 AM

-12:00 AM

Dr. Xiaohua Wu

Final survival outcomes and exploratory biomarker analysis from the randomized, phase 2 neoSCORE trial: Two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small cell lung cancer

.

8048

Poster Session

-Lung Cancer

-Non-Small Cell Local

-Regional/Small Cell/Other Thoracic Cancers

6/3/2024

1:30 PM

-4:30 PM

Dr.Fuming Qiu

Olverembatinib

Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) and paraganglioma

11502

Oral Abstract Session

-Sarcoma

6/3/2024

3:00 PM

-6:00 PM

Dr. Haibo Qiu

On April 24, 2024 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that an abstract presenting preliminary data from the phase 2 combination study of AFM24, its innate cell engager (ICE), in combination with atezolizumab, Roche’s checkpoint inhibitor, in patients with EGFR-wildtype (EGFRwt) non-small cell lung cancer (NSCLC) has been accepted for poster presentation at 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Affimed, APR 24, 2024, View Source [SID1234642305]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:

Title: Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC)

Presenting Author: Hye Ryun Kim

Poster Session: Developmental Therapeutics—Immunotherapy

Abstract Number: 2522

Poster Presentation Time: Saturday, June 1, 2024, 9:00 a.m. – 12:00 p.m. CDT

The full abstract will become available on ASCO (Free ASCO Whitepaper)’s website on May 23, 2024 at 5:00 p.m. (EDT). More details about the ASCO (Free ASCO Whitepaper) conference are available online at Attend | ASCO (Free ASCO Whitepaper) Annual Meeting.

About AFM24
AFM24 is a tetravalent, bispecific ICE that activates the innate immune system by binding to CD16A on innate immune cells and epidermal growth factor receptors (EGFR), a protein widely expressed on solid tumors, to kill cancer cells. Generated by Affimed’s fit-for-purpose ROCK platform, AFM24 represents a distinctive mechanism of action that uses EGFR as a docking site to engage innate immune cells for tumor cell killing through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.

On April 24, 2024 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that the abstract for longer-term follow-up and additional data analysis from the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) was selected for an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, (May 31 – June 4, 2024, Chicago) (Press release, Autolus, APR 24, 2024, View Source [SID1234642304]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ASCO Oral Presentation, abstract #6504:
Title: Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX Phase Ib/II study
Session Title: Oral Abstract Session – Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session date and time: Friday, May 31, 2024, 14:45 – 17:45 EDT, 19:45 – 22:45 BST
Presenting Author: Dr Elias Jabbour, Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX

A conference call and webcast to discuss the presented data will be held at 9:30 am EDT/2:30 pm BST on Saturday June 1, 2024. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.